Cytokinetics, Incorporated
CYTK
주식 순위
#2306
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
주가
$64.24
시가총액
$8.93B
변동 (1일)
2.54%
변동 (1년)
8.24%
국가
US
거래 Cytokinetics, Incorporated (CYTK)
카테고리
Healthcare
Cytokinetics, Incorporated (CYTK)의 발행 주식 수
June 2026 기준 발행 주식 수: 132.09M
Cytokinetics, Incorporated의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 132.09M입니다. December 2023 말 기준 회사는 96.52M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Cytokinetics, Incorporated (CYTK)의 발행 주식 수 기록 (2000 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 132.09M | 17.96% |
| 2024 | 111.98M | 16.01% |
| 2023 | 96.52M | 7.46% |
| 2022 | 89.83M | 16.83% |
| 2021 | 76.89M | 19.16% |
| 2020 | 64.52M | 12.07% |
| 2019 | 57.58M | 5.80% |
| 2018 | 54.42M | 10.15% |
| 2017 | 49.40M | 23.69% |
| 2016 | 39.94M | 3.32% |
| 2015 | 38.66M | 8.27% |
| 2014 | 35.71M | 30.92% |
| 2013 | 27.28M | 50.63% |
| 2012 | 18.11M | 53.45% |
| 2011 | 11.80M | 10.34% |
| 2010 | 10.69M | 11.81% |
| 2009 | 9.57M | 16.19% |
| 2008 | 8.23M | 3.79% |
| 2007 | 7.93M | 29.96% |
| 2006 | 6.10M | 28.12% |
| 2005 | 4.76M | 44.51% |
| 2004 | 3.30M | 935.01% |
| 2003 | 318.50K | 9.70% |
| 2002 | 290.33K | 22.69% |
| 2001 | 236.64K | 47.10% |
| 2000 | 160.87K | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | 92.22% |
US
|
|
| 396.00M | 199.80% |
US
|
|
| 478.91M | 262.58% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -52.92% |
NL
|
